The prevalence of NAFLD having elevation of ALT in Non-MS, Pre-MS, and MS groups were 5.1% (115/2,246), 28.8% (104/361), and 44.3% (185/418), respectively. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.